VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)
$109.7 2.1768 (2.0245%)
Analysed VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) News Sources
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
04-02-2026
yahoo.com
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
23-03-2026
yahoo.com
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
28-03-2026
247wallst.com
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
30-03-2026
yahoo.com
AbbVie Stock: Is Wall Street Bullish or Bearish?
11-05-2026
barchart.com
Sickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.
24-05-2026
barchart.com
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF
02-06-2026
barchart.com
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
05-06-2026
yahoo.com
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
10-06-2026
yahoo.com
4 ETF Winners of June Likely to Gain in July
08-07-2026
yahoo.com
What is the current price of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)?
The current price of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) is $109.7.
VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) absolute price change since previous trading day?
The absolute price change of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) since the previous trading day is $2.1768.
VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) percentage price change since previous trading day?
The percentage price change of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) since the previous trading day is 2.0245%.
What is the most recent average sentiment score for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)?
The most recent average sentiment score for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) is 63 out of 100.
What is the most recent average sentiment for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)?
The most recent sentiment for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) is .
SEC-8K** Filing Available For VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.